Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | DRD1 | P21728 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802062 | 0.84 | DRD3 (0.59) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| SCHEMBL8938186 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL2476701 | 0.82 | MAPK1 (0.60) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| SCHEMBL9256722 | 0.82 | CYP2D6 (0.48) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| SCHEMBL9565893 | 0.82 | IDO1 (0.51) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| SCHEMBL12064955 | 0.82 | IDO1 (0.50) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| SCHEMBL9352969 | 0.82 | DRD3 (0.54) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL9353200 | 0.81 | IDO1 (0.53) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| Alcohol SCHEMBL7226806 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A | |
| Acetic Acid SCHEMBL2472607 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A3CYP2D6CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | VERNALIS RESEARCH LIMITED. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1618105-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096794-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-0529365-A1 | Diarylmethoxypiperidine derivatives | Kaken Pharmaceutical Co., Ltd. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5190959-A | Antihistamines, antiallergens, treatment of ischemic heart disease | KAKEN PHARMACEUTICAL CO. LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | CNR1, CNR2, GPR119 | SLC6A2 760/4885SLC6A3 513/4885CYP2D6 280/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | SLC6A2 587/4885SLC6A3 294/4885CYP2D6 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.